Figure 2. Metronomic paclitaxel/perifosine combination is highly effective in mice bearing human NSCLC xenografts.

Perifosine was administered by oral gavage 5 days/week throughout the study (a–f), and paclitaxel was administered either once daily the first five days (a–d) or chronically twice a week throughout the study (e–f) as shown by arrows (n = 5). (a,c,e) Tumor volumes were measured. Significant differences compared to vehicle. (b,d,f) Weights of mice and (G) Kaplan-Meier survival curves (n = 10) from the same groups. (h) Representative pictures of tumors after dissection. Tumor weight was recorded. Significant differences compared to vehicle. (i) Immunohistochemical staining of the nuclear proliferation marker Ki67. Percentage of Ki67-positive cells with significant differences compared to vehicle.